On Thursday, Twitter Inc (NYSE:TWTR)’s shares declined -0.71% to $26.60.
In an analyst note released on Thursday, 24 September, Twitter (TWTR) stock had its “Neutral” Rating restate by investment analysts at Citigroup. They presently have a $30 TP on company. Citigroup’s target would suggest a potential upside of 17.14% from the company’s last close price.
Out of 34 analysts covering Twitter, 16 rate it a Buy, 25 indicate a Hold while 1 suggest a Sell. The highest target is $56 and the lowest is $26 according to Thomson/First Call. The 12-month mean target is $39.29, which means upside potential of 53.48% over the current price.
Twitter, Inc. (Twitter) is a global platform for public self-expression and conversation in real time. The Company offers products and services for users, advertisers, developers and platform and data partners. Products and services for users enables a way for people to create, distribute and discover content, which enables a user on Twitter to create a tweet and a user to follow other users.
Netflix, Inc. (NASDAQ:NFLX)’s shares gained 5.80% to $103.76.
In support of the second season premiere on Thursday, September 24 of ABC’s critically acclaimed series, “How To Get Away With Murder,” Netflix, Inc. and ABC recently declared a fully global agreement making Netflix the exclusive worldwide streaming home of the first season of the hit drama. Season one episodes of the series will arrive in the U.S., Canada and Latin America on September 18, and all remaining and future territories starting in Q4 2015 or 2016.
Netflix, Inc. is a provider of Internet television network. The Company has over 57 million streaming members in over 50 countries. Its members can watch more than two billion hours of television (TV) shows and movies per month, counting original series, documentaries and feature films on Internet-connected screen.
At the end of Thursday’s trade, Pfizer Inc. (NYSE:PFE)‘s shares surged 0.34% to $32.73.
As part of the global planned alliance between Merck and Pfizer to jointly develop and commercialize avelumab*, an investigational immune checkpoint inhibitor, the companies have declared recently that they have a partnership agreement in place with Dako, an Agilent Technologies company, for the development of a potential companion diagnostic test (CDx).
The three-party agreement, signed recently, enables Dako, Merck and Pfizer to work to develop the CDx to assess programmed death-ligand 1 (PD-L1) protein expression levels in tumor tissue, and its microenvironment, counting tumor-associated immune cells. The investigational CDx is part of the protocols in ongoing clinical trials of avelumab, some of which will be stated at forthcoming scientific congresses.
The financial terms of the agreement were not revealed.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products comprise Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others.
Medtronic PLC (NYSE:MDT), ended its Thursday’s trading session with -1.31% loss, and closed at $63.38.
Medtronic has launched a 2,500-patient global study of its SuperDimension system for diagnosing lung cancer, according to Business Journals.
The technology uses a CT scan to map a patient’s lungs and guide the doctor to a potentially cancerous lesion for investigation. The electromagnetic navigation bronchoscopy procedures are minimally invasive.
Medtronic anticipates the study will “support and validate the superDimension system, which the company hopes will become the global standard-of-care for obtaining lung tissue biopsies from the periphery of the lungs.” It said the first patient got the procedure in April. Business Journals Reports
Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in about 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
